^
    20d
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Completed, Universität des Saarlandes | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2024 | Trial primary completion date: May 2025 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    3ms
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Recruiting, Medical College of Wisconsin | Trial completion date: May 2028 --> May 2026 | Trial primary completion date: May 2027 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    1year
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Active, not recruiting, Universität des Saarlandes | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    1year
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Active, not recruiting, Universität des Saarlandes | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    over1year
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    over1year
    Primary extranodal soft tissue Lennert lymphoma (lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified): a case report and review of the literature. (PubMed, Diagn Pathol)
    The patient received four cycles of cyclophosphamide, doxorubicin liposomes, vincristine, and prednisone tablets (CHOP) and was followed for 20 months. Overall treatment efficacy was achieved without lymphadenopathy, and no other discomfort or illnesses were reported.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • SSTR2 (Somatostatin Receptor 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    CD4 positive
    |
    cyclophosphamide • Marqibo (vincristine liposomal)
    over1year
    ECOG-ACRIN EA9152: Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Recruiting, ECOG-ACRIN Cancer Research Group | Suspended --> Recruiting
    Enrollment open • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • Marqibo (vincristine liposomal)
    over1year
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Active, not recruiting, Universität des Saarlandes | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    over1year
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Medical College of Wisconsin | Initiation date: Aug 2022 --> Dec 2022
    Trial initiation date • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    almost2years
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Medical College of Wisconsin | Initiation date: May 2022 --> Aug 2022
    Trial initiation date • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    almost2years
    ECOG-ACRIN EA9152: Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Suspended, ECOG-ACRIN Cancer Research Group | Trial completion date: Apr 2021 --> Dec 2028 | Recruiting --> Suspended | Trial primary completion date: Apr 2021 --> Dec 2028
    Trial completion date • Trial suspension • Trial primary completion date • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • Marqibo (vincristine liposomal)
    2years
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Medical College of Wisconsin
    New P1 trial • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    2years
    Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL (clinicaltrials.gov)
    P2, N=0, Withdrawn, Dorothy Sipkins, MD, PhD | N=35 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD19 (CD19 Molecule)
    |
    Blincyto (blinatumomab) • Marqibo (vincristine liposomal)
    over2years
    Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1b/2, N=0, Withdrawn, Roswell Park Cancer Institute | N=42 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
    over2years
    EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (clinicaltrials.gov)
    P1, N=3, Terminated, University of Southern California | N=44 --> 3 | Recruiting --> Terminated; Study drug supply issue
    Clinical • Enrollment change • Trial termination • Combination therapy
    |
    EPHB4 (EPH receptor B4)
    |
    sEphB4-HSA • Marqibo (vincristine liposomal)
    over2years
    Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia (ASH 2021)
    The primary objectives are to evaluate whether the combination will result in a median PFS of ≥1 year, and if the CR/CRi rate is ≥75% following 2 cycles and duration of remission. Secondary outcomes will include evaluation of the rate of Minimal Residual Disease (MRD) and duration, the proportion of patients who are able to progress to allogeneic transplantation, the safety of blinatumomab and liposomal vincristine sulfate in combination and the effect of the combination and response on measures of immune reconstitution.
    Clinical • P2 data
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    Blincyto (blinatumomab) • Marqibo (vincristine liposomal)
    over2years
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Active, not recruiting, Universität des Saarlandes | Trial primary completion date: Jun 2021 --> Dec 2021
    Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • Marqibo (vincristine liposomal)
    over2years
    Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • CD2 (CD2 Molecule)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • Marqibo (vincristine liposomal)
    over2years
    Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL (clinicaltrials.gov)
    P2, N=35, Suspended, Dorothy Sipkins, MD, PhD | Not yet recruiting --> Suspended
    Clinical • Trial suspension
    |
    CD19 (CD19 Molecule)
    |
    Blincyto (blinatumomab) • Marqibo (vincristine liposomal)
    almost3years
    Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1b/2, N=42, Recruiting, Roswell Park Cancer Institute | Trial completion date: Feb 2023 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
    over3years
    Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1b/2, N=42, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
    over4years
    Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma (clinicaltrials.gov)
    P3, N=665, Active, not recruiting, Children's Oncology Group | Completed --> Active, not recruiting | Trial completion date: Feb 2015 --> Feb 2022
    Clinical • Enrollment closed • Trial completion date
    |
    CD8 (cluster of differentiation 8) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CD4 (CD4 Molecule)
    |
    MYCN amplification • UGT1A1*1*1
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • topotecan • melphalan • Marqibo (vincristine liposomal) • thiotepa • Neupogen (filgrastim)